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Abstract
Aims To investigate the effect of a range of demographic
and psychosocial variables on medication adherence in
chronic obstructive pulmonary disease (COPD) patients
managed in a secondary care setting.
Methods A total of 173 patients with a confirmed diagnosis
of COPD, recruited from an outpatient clinic in Northern
Ireland, participated in the study. Data collection was carried
out via face-to-face interviews and through review of
patients’ medical charts. Social and demographic variables,
co-morbidity, self-reported drug adherence (Morisky scale),
Hospital Anxiety and Depression (HAD) scale, COPD
knowledge, Health Belief Model (HBM) and self-efficacy
scales were determined for each patient.
Results Participants were aged 67±9.7 (mean ± SD) years,
56 % female and took a mean (SD) of 8.2±3.4 drugs. Low
adherence with medications was present in 29.5 % of the
patients. Demographic variables (gender, age, marital status,
living arrangements and occupation) were not associated with
adherence. A range of clinical and psychosocial variables, on
the other hand, were found to be associated with medication
adherence, i.e. beliefs regarding medication effectiveness,
severity of COPD, smoking status, presence of co-morbid
illness, depressed mood, self-efficacy, perceived susceptibility
and perceived barriers within the HBM (p<0.05). Logistic
regression analysis showed that perceived ineffectiveness of
medication, presence of co-morbid illness, depressed mood
and perceived barriers were independently associated with
medication non-adherence in the study (P<0.05).
Conclusions Adherence in COPD patients is influenced
more by patients’ perception of their health and medication
effectiveness, the presence of depressed mood and co-
morbid illness than by demographic factors or disease
severity.
Keywords Adherence . COPD . Health beliefs .
Depression . Self-efficacy . Disease knowledge
Introduction
Chronic obstructive pulmonary disease (COPD) is often asso-
ciated with a constant deterioration in health leading to a belief
among patients that they are not going to readily benefit from
their treatment, and it has been shown that a significant pro-
portion of COPD patients have poor adherence to prescribed
treatment [1–5]. Poor adherence of COPD patients to drug
therapy and disease management programmes has been iden-
tified as a major factor resulting in emergency hospitalisation
in addition to sub-optimal clinical outcomes [6, 7]. Several
factors could predispose COPD patients to non-adherence.
First, the management of COPD is complex and requires
several behavioural and lifestyle changes such as smoking
cessation and adherence to exercise programmes and prescribed
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medication [8]. In addition, multiple co-morbidities are
common in COPD patients; they are often prescribed
complex medication regimens comprising scheduled and
as-needed medications, delivered by multiple administra-
tion routes. Depression, a common co-morbidity in
patients with COPD, is also known as a potential risk
factor for non-adherence [7, 9, 10].
Older age and disease duration are additional factors that
may contribute to non-adherence since they are associated
with increased risk of cognitive impairment and memory
problems [11]. Interruptions or changes in normal routines,
adverse side effects, running out of medication and poly-
pharmacy have also been associated with non-adherence.
Strategies to improve COPD patient adherence include
establishing a personal relationship or partnership in
which the patient feels able to discuss their fears, con-
cerns and personal goals. Synchronising dosing times and
simplifying regimens can help improve non-adherence
resulting from forgetfulness, but are unlikely to promote
deliberate non-adherence due to barriers such as patient
beliefs that medicines are no longer needed [12] or con-
cerns about side-effects [13]. Patient education and pro-
vision of information about COPD and its treatment can
play an important role in modifying beliefs and under-
standing, hence potentially improving adherence.
The aim of the present study was, therefore, to examine
the effect of a range of potential clinical and psychosocial
variables on adherence to medication in COPD patients
managed in a secondary care setting.
Methods
Study subjects
A total of 173 patients (mean age 67; 56 % females), with
moderate to severe COPD were recruited from the outpatient
COPD clinic at the Mater Hospital, Belfast, Northern Ireland.
All COPD patients who attended the clinic were invited to
participate. Other inclusion criteria included confirmed diag-
nosis of COPD for at least 1 year by their hospital consultant,
having an FEV1 value of 30–80 % of the predicted normal
value and being over 45 years old. Patients who had a heart
failure, moderate to severe learning difficulties (as judged by
hospital consultant), severe mobility problems, terminal
illness or who had attended a pulmonary rehabilitation
programme in the last 6 months were excluded from the study.
All clinical data were obtained from patients’ medical charts.
This study was part of a larger research project on a self-
management intervention programme for COPD patients
[14]. The study was approved by the Office of Research
Ethics Committees in Northern Ireland (ORECNI; 06/
NIR02/23).
Instruments
Various validated instruments were used in this study to
investigate the potential effect of the tested variables, i.e.
the self-reported adherence (Morisky scale), the Hospital
Anxiety and Depression (HAD) scale, COPD knowledge
questionnaire, the COPD self-efficacy scale, the perceived
medication effectiveness scale and the Health Belief Model
(HBM) questionnaire. Further details about these six instru-
ments are presented below.
Self-reported adherence (Morisky scale) The self-report
Morisky adherence scale [15] was used to measure patients’
adherence to their COPD-related medications over the
4 weeks preceding their clinic visit. This scale measures
adherence through four yes/no response items: forgetting,
carelessness, stopping medication when feeling better and
stopping medication when feeling worse. Each ‘yes’ re-
sponse is given a score of one and each ‘no’ response is
scored zero (total adherence scores range between 0 and 4).
Two adherence classifications were used, i.e. high adher-
ence (scores of 0–1) and low adherence (scores of 2–4). The
Morisky scale has good validity and reliability; Cronbach’s
alpha00.61 [15].
Hospital Anxiety and Depression (HAD) scale The HAD
scale is a 14-item self-report questionnaire designed to
detect psychological morbidity in medically ill patients
[16]. It contains depression and anxiety subscales, each
scoring 0–21. A score above 8 on either subscale can be
used to screen for possible depression and anxiety and a
score above 11 for a probable disorder. A score of less than
8 on the depression scale is considered normal, 8–10 is mild
depression, 11–14 is moderate and 15 or above represents
severe depression. The HAD scale is a valid measure of
depression and anxiety with Cronbach’s alpha values of
0.83 for anxiety and 0.82 for depression [17].
COPD knowledge questionnaire This instrument was devel-
oped by Scherer [18] to assess the effectiveness of patient
education in COPD patients. It consists of 16 true/false items
relating to the pathophysiology of COPD, breathing and
exercise, energy conservation, medications, relaxation and
stress control. Correct responses for each item are scored 1
and incorrect or unsure responses are scored 0 (total range
0–16). The instrument has been shown to be valid, with a
Cronbach’s alpha for internal consistency of 0.89 [18].
Health Belief Model (HBM) questionnaire The HBM has
been widely used as a conceptual framework to explain
and predict health behaviours by focusing on the beliefs
and attitudes of individuals [19–22]. The model attempts
to define the individual’s motivation for adopting a
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health-promoting behaviour. The model includes four
primary variables: perceived susceptibility (e.g. belief of
vulnerability to disease relapse as a result of not taking
the medication when not experiencing symptoms directly),
perceived severity (or seriousness of the health threat),
perceived benefits (e.g. individual’s belief in the efficacy
of the prescribed medication in reducing disease severity
or susceptibility) and perceived barriers (e.g. stigma of
taking medication or denial of having serious illness)
[19, 20]. The questionnaire rates variables on a 5-point
Likert scale. The HBM questionnaire was completed
only by the intervention group at baseline of the main
study [14]; data were available for 83 (96.5 %) of that
group.
COPD Self-Efficacy Scale (CSES) The CSES was used to
assess the level of confidence of COPD patients in their
ability to manage or avoid breathing difficulty while
participating in certain activities [23]. The instrument
contains 34 items (5-point Likert scale), with higher
scores indicating greater perceived self-efficacy. These
items are categorised into five subscales which include
negative affect, intense emotional arousal, physical exer-
tion, weather/environment and behavioural risk factors.
Good test-retest reliability (r00.77) and internal consis-
tency (Cronbach’s alpha00.95) have been reported [23].
A mean score was calculated in the present study by
summing the response scores for each item and dividing
them by the number of items answered.
Medication effectiveness Patients were also asked to rate
their perceived medication effectiveness and their faith in their
prescribed medication as totally effective, mostly effective,
partially effective or totally not effective.
All questionnaires were administered to patients via a
face-to-face interview at the hospital clinic.
Data analysis
Statistical analyses were performed using SPSS version 19
(SPSS, Chicago, IL, USA). Associations between the depen-
dent variable (adherence category) and other potential explan-
atory variables, the chi-squared test or the Fisher exact test
were used, as appropriate, for categorical variables. Student’s
t-tests and the Mann-Whitney U-tests were used for paramet-
ric and non-parametric continuous variables respectively.
For further investigation of factors influencing the depen-
dent variable, binary stepwise conditional logistic regression
analysis was utilised. Variables with a probability of <0.25
in the univariate analysis were included in this latter analysis
[24]. A p-value < 0.05 was considered statistically signifi-
cant (two-sided test) in all cases.
Results
Demographics and disease characteristics
The demographic characteristics of participants are pre-
sented in Table 1. Completed questionnaires were available
for all patients recruited (n0173). Medical and disease char-
acteristics of the study population are shown in Table 2. The
mean number (±SD) of prescribed medications per patient
was 8.2 (±3.4). Most of the patients had moderate to severe
disease according to the British Thoracic Society (BTS,
2006) guidelines and 21 % were active smokers.
Demographic variables and adherence to COPD
medications
Of the 173 participants, 29.5 % (n051) were classified in
the low-adherence group (scoring 2–4 on Morisky scale).
Figure 1 summarises patient responses to individual items of
the scale. Missed dose (forgetfulness) was the most preva-
lent type of non-adherence, i.e. reported by 33 % of the
respondents overall and by 68 % of the low adherence
group. Statistical analyses indicated no significant correla-
tions between adherence groups and demographic variables,
including gender, marital status, age, living arrangements,
occupation and level of education (Table 3).
Table 1 Characteristics of study population (n0173)
Variable Frequency, n (%)
Gender
Male 75 (43.4)
Female 98 (56.6)
Age (mean, SD, years) 66.6 (9.7)
Marital status
Single 9 (5.4)
Married 103 (62.0)
Separate 15 (9.0)
Widowed 39 (23.5)
Living arrangements
Independently 28 (16.8)
With friends 2 (1.2)
With family 119 (71.3)
24-h supervised accommodation/hostel 6 (3.6)
Alone but with support 12 (7.2)
Educational level
Primary school 49 (28.3)
Secondary/tertiary 124 (71.7)
Occupation
Low 110 (63.5)
Medium 38 (22.4)
High 25 (14.5)
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Medical and disease characteristics and adherence to COPD
medications
Disease severity and presence of co-morbid illnesses A
significant association (p<0.05) was found between COPD
disease severity stages (Table 3) and adherence groups.
Review of patient charts revealed that 49.1 % had one or
more co-morbid illness which required medications, includ-
ing heart disease (21.4 %), osteoporosis (17.9 %) and
hypertension (9.8 %). A significant relationship was also
found between the presence of co-morbid conditions and
adherence groups (p<0.01), i.e. higher percentage of the
patients with no co-morbid illness were classified within
the high adherence category.
Knowledge about COPD medications and disease manage-
ment Patients who had lower knowledge scores were more
likely (p<0.01) to be in the low-adherence group (Table 3;
Fig. 2).
Effectiveness of the prescribed medications No significant
association (p>0.05) was found between the mean number
of prescribed medications and medication adherence. How-
ever, a significant association (p<0.01) was found between
self-report of the effectiveness of medications and adherence
Table 2 Medical and disease characteristics of study population (n0173)
Variable Frequency, n (%)
Disease severity (BTS)
Mild (60–79) 35 (20.5)
Moderate (40–59) 90 (52.6)
Severe (<40) 46 (26.9)
FEV1 (mean, SD)
L 1.17 (0.5)
% predicted 52.6 (16.8)
FEV1/FVC 56.6 (10.0)
Number of prescribed medications (mean, SD) 8.2 (3.4)
Years of diagnosis (mean, SD) 6.5 (5.1)
Medications, n (%)
Short-acting β2-agonists 163 (94.2)
Long-acting β2-agonists 137 (79.2)
Long-acting anti-cholinergic 130 (75.1)
Inhaled steroids 114 (65.9)
Oral steroids 16 (9.2)
Effectiveness of the medication
Totally/mostly effective 107 (63.7)
Little/not effective 61 (36.3)
Co-morbid illness
Co-morbid illness present 85 (49.1)
No co-morbidity 88 (50.9)
Smoking status
Ex-smokers 113 (65.3)
Current smokers 37 (21.4)
Never smoked 23 (13.3)
HAD scores (mean, SD)
Anxiety scores 8.28 (4.3)
Depression scores 8.27 (4.2)
BTS British Thoracic Stages, HAD Hospital Anxiety and Depression
scale
Fig. 1 Patient responses to self-report adherence items
Table 3 Univariate analysis of the association of potential demographic
and clinical variables with self-reported adherence
Potential explanatory variables p-value
Gender >0.25a
Age >0.25b
Marital status >0.25a
Living arrangements <0.25a
Occupation >0.25a
Education >0.25a
Smoking status <0.05a
Disease and medication knowledge <0.01b
Self-efficacy <0.01b
Number of prescribed medications >0.25b
Medication effectiveness <0.01a
Disease severity <0.05a
HAD anxiety <0.25b
HAD depression <0.01b
Co-morbid illness <0.01a
Duration of COPD disease <0.25b
HBM perceived susceptibility score <0.01b
HBM perceived barriers score <0.01b
HAD Hospital Anxiety and Depression scale, COPD chronic obstructive
pulmonary disease, HBM Health Belief Model
a Chi-squared test or Fisher exact test, as appropriate
bMann-Whitney U-Test or Student’s t-test, as appropriate
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behaviour (Fig. 3), i.e. those patients who felt that their
medications were totally or mostly effective were more
likely to report adherence to their medications.
Self-efficacy and smoking status Participants with higher
COPD self-efficacy scores were more likely to be classified
as adherent (Table 3; Fig. 4). Patients who still smoked were
more likely to be non-adherent with their medication (Table 3).
Hospital anxiety and depression scale scores In the low
adherence group, depression, i.e. HAD score of 11 or more,
was evident in 52.4 % of patients versus 27.7 % in the high
adherence group (p<0.01). There was no significant difference
between high and low adherence group patients with regard to
anxiety scores.
Health Belief Model Medication adherence behaviour was
correlated with the perceived susceptibility (e.g. relapse or
exacerbation as a result of not taking the medication,
p<0.01) and with perceived barriers to medication use
(e.g. stigma of taking medications, concerns about side
effects or denial of serious illness; p<0.01; Table 3). No
association was found for perceived severity or benefits of
medication use (p>0.05).
Binary logistic regression analysis of self-reported
adherence
Following the modelling strategy of Homer and Lemeshow
[24], the explanatory variables with a p-value <0.25 (Table 3)
were subjected to logistic regression analysis to further ex-
plore associations between the potential explanatory variables
and self-reported adherence.
The final model included depression status, views on
medication effectiveness and presence of co-morbid condi-
tions. Those who had HAD scores indicative of depression
and those with co-morbid illness were 8.9 times and 5.0
times respectively more likely to be classified as non-
adherent. Conversely those who believed that their medica-
tion was effective were more likely to be deemed adherent
(OR00.09 for non-adherence). A test of the final model
against a constant only model was statistically reliable (p<
0.05) indicating that the predictors were able to reliably
distinguish between adherent and non-adherent participants
in this sample. This model explained 45.8 % (Nagelkerke
R2) of the variation in adherence. A non-significant results
(p>0.05) for the Hosmer test was evidence that the model
has good fit to the data. An overall success rate of 83.6 %
was found using the developed model, i.e. 90.0 % of
adherent and 66.7 % of non-adherent were correctly
Fig. 2 Box and whisker plot of the association between COPD
knowledge scores and self -reported adherence
Fig. 3 Influence of self-reported medication effectiveness on self-
reported adherence behaviour
Fig. 4 Box and whisker plot of the association between COPD
self-efficacy scores and self-reported adherence
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classified. A separate regression analysis of the sub-group of
patients who answered the Health Belief Model revealed
‘perceived barriers’ as an additional significant variable in
the final regression model. This model explained 51.9 % of
adherence variability with an overall success rate of 83.0 %.
Table 4 shows the estimated odds-ratios and the 95 % con-
fidence intervals for each of the predictors in the two
models.
Discussion
Adherence research in COPD has mainly focused on quan-
tification of adherence, with few studies attempting to iden-
tify factors influencing non-adherence [2, 7, 8, 25]. Prior to
the present study, the patient perspective relating to adher-
ence had been largely neglected.
Although the sample size was reasonably small (n0
173), this should be adequate to achieve reliability and
confidence in the results obtained [26]. While self-report
is an indirect measure of medication adherence, it has
been shown to be as effective as other indirect measures,
including pill counts and refill rates [10] and was the
most practical for the present study. More precise esti-
mates of medication adherence can be gained via direct
methods (e.g. observation, drug or metabolites blood
concentrations), however, such methods are expensive,
burdensome or invasive [10].
Using the classification system described, 29.5 % of
the study participants were placed within a low adher-
ence group. This fell within the expected range reported
in earlier studies [27, 28]. In agreement with a smaller
study in this area [2], no significant associations were
found between demographic variables (gender, age,
marital status, living arrangements and occupation) and
self-reported adherence.
Approximately half of the patients in the present study had
co-morbidities; a significant relationship between non-
adherence and co-morbidity presence was identified (odds ratio
of 5.0 in the final logistic regression model; p<0.05). This was
regardless of the number of medications patients received,
which did not have sufficient association to be included in the
multivariate analysis (p>0.25). Statistical analysis also failed to
identify a significant relationship between duration of the dis-
ease and adherence group classification, although both of these
factors have previously been found to negatively affect adher-
ence [29]. Findings in the latter study, however, are not consis-
tent across adherence research, e.g. Horne et al. found that the
number of prescribed medications was unrelated to adherence
in a group of hypertensive patients [30].
A significant association (p<0.01) was also found be-
tween COPD knowledge scores and adherence, with lower
knowledge scores more likely within the low-adherence
group (Fig. 2). This finding is consistent with the work of
Johnson et al. [8] who concluded that COPD patients clas-
sified as adherent had a greater understanding about their
illness and options for its management. There are, however,
mixed findings in the literature regarding the relationship
between knowledge and adherence. In a recent study by
Scherer et al., higher education level was correlated with
higher knowledge scores, however, attitudes and self-
efficacy rather than knowledge had the most significant
impact on adherence [31]. Studies evaluating the effect of
educational interventions on adherence to medication in
COPD patients have also shown varied and inconsistent
results [32, 33]. Promising results, however, were reported
recently by studies that offered educational programmes to
COPD patients that emphasised illness control through
health behaviour modification [34–36]. Such educational
programmes have been shown to empower patients to self-
manage their chronic health condition and to promote
adherence [36]. In the present study, however, knowledge
score did not have sufficient association to remain as an
independent predictor of adherence in the final regression
model.
Table 4 Final logistic regression models predicting self-reported
adherence
Variables OR (95 % CI) p-value
Logistic regression analysis for the whole group (n0173)
Medication effectiveness
Totally or most effective 0.094 (0.017–0.517) <0.01
Little or no effectiveness Reference
Co-morbid illness
No presence of co-morbid disease 5.02 (1.0–25.2) <0.05
Presence of co-morbid disease Reference
Depression category
Depressed (score 11 or more) 8.95 (1.8–44.1) <0.01
Not depressed (score less than 11) Reference
Logistic regression analysis for the subset who answered HBM (n083)
Medication effectiveness
Totally or most effective 0.082 (0.015–0.46) <0.01
Little or no effectiveness Reference
Co-morbid illness
Presence of co-morbid disease 9.03 (1.6–49.9) <0.05
No presence of co-morbid disease Reference
Depression category
Depressed (score 11 or more) 8.77 (1.8–43.8) <0.01
Not depressed (score less than 11) Reference
HBM perceived barriers
Perceived barriers to taking medication 1.24 (1.02–1.5) <0.05
No perceived barriers Reference
HBM Health Belief Model
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The HBM model is widely accepted as a tool to measure
patient motivations to accept, and subsequently adhere to, a
prescribed preventive treatment. It lends itself to the predic-
tion of medication adherence since it includes various psy-
chological factors that influence the person’s capacity to act
[19, 20, 37]. The HBM suggests that a behavioural change is
dependent upon perceived illness severity and perceived sus-
ceptibility to harm or serious health consequences if the
disease is left untreated. In addition, the patient’s perception
of the effectiveness or benefit of the recommended treatment
weighed against the perceived barriers to action (e.g. potential
side effects of treatment or denial of illness) predicts the
likelihood of taking or adhering to that treatment [19, 38].
Therefore, it has been concluded that higher adherence to a
prescribed treatment (particularly in case of chronic condi-
tions such as COPD) requires both an acceptance of the illness
and confidence in medication effectiveness [7, 39–41].
In the present study, the HBM construct of perceived
barriers was a better predictor of adherence than other com-
ponents of HBM (perceived severity, susceptibility and bene-
fits) or the objective severity of the disease (disease activity) in
the multiple regression analysis. Perceived barriers contribut-
ed significantly to the final regression model and explained a
significant percentage of the variance in adherence (7.1 %;
p<0.05). Other HBM components and objective severity
were not sufficiently associated to be included in the regres-
sion model, however, when considered in a bivariate relation-
ship with adherence, both perceived susceptibility and
objective disease severity were significantly associated with
adherence (p<0.01 and p<0.05 respectively). These findings
concur with earlier studies which suggest that a patient’s
perceived need for the treatment is not directly associated with
the objective measures of severity of the disease [42, 43].
For chronic illnesses, self-efficacy, which relates to the
person’s perceived capability of carrying out an intended
behaviour [44], can be an important predictor of adherence
behaviour [45]. However, in the present study self-efficacy
did not explain a significant proportion of the variance in
adherence and, hence, was not incorporated in the final
logistic regression model.
Thirty-five percent of the participants in the present study
had HAD scores indicative of anxiety and 34.5 % had scores
indicative of depression. A significant correlation was found
between depression (but not anxiety) and low adherence
behaviour (p<0.01). In addition, depression was a signifi-
cant predictor of non-adherence in the regression model and
explained 22 % of the variance in adherence (OR08.95;
p<0.01). In the UK, the National Institute of Clinical
Excellence COPD Guidelines estimated the prevalence of
depression in COPD to be 40 % (36–44 %) and suggested
that anxiety symptoms may have a prevalence of 36 % (31–
41 %) [9]. Having a co-morbid illness in the present study
was found to increase depressive symptom scores, i.e.
participants who did not have any co-morbidity had a mean
HAD score of 7.08, whilst those who did have co-morbidity
had a mean HAD score of 9.19 (p<0.01). Both co-morbidity
and depression status remained significant in the final logis-
tic regression model.
A meta-analysis has found that depression is associated
with non-adherence to medical advice in a number of dis-
ease states [46]. Although there has been little research to
date in COPD patients, the few studies which have been
carried out have shown a significant relationship between
depression and poor adherence [47]. Research is required to
determine whether treating depression can enhance adher-
ence to medical advice and reduce morbidity and mortality
risk in COPD patients [47].
The results of the present study also revealed that those
patients who felt that their medications were totally or
mostly effective were more likely to be adherent (p<0.01),
as predicted by the HBM. This is in line with research in
other patient groups [7, 39–41].
Interestingly, the variance in adherence explained by the
factors identified in the present study (45.8 % for the whole
group and 51.9 % when HBM ‘perceived barriers’ were
included in the regression model) was higher than that
reported by other models of adherence [21, 30, 43, 48, 49].
For instance, a model described by George et al. [48]
explained only 19.5 % of variance in non-adherence in a
COPD population. Another recent study described a linear
regression model explaining 31.8 % of variance in reported
adherence to continuous positive airway pressure therapy in
patients with COPD [43]. In the latter model, patients’ beliefs
about their medicines were the strongest predictors, account-
ing for 21.8% of the variance. One possible reason for the low
fraction of variance explained in any model of adherence
could be the discrepancies between true and self-reported
adherence, in that non-adherent subjects tend to exaggerate
their degree of adherence [50]. This is supported by the fact
that the classification success rate for the present model was
90 % in patients who were adherent to therapy, but was
66.7 % for those who were non-adherent to medication.
Conclusion
The key finding in the present study was that patient views
on medication effectiveness and the presence of depression
or co-morbid illnesses were found to be more powerful
predictors of reported adherence than socio-demographic
factors or other clinical factors. In addition, the present
findings support the utility of HBM for the prediction of
non-adherence to medication in COPD patients. Future re-
search should focus on highlighting further variables, which
may inform interventions aimed at improving adherence to
COPD medication.
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